文献库搜索 | GeneLibs

Kolb(H),Hartwig(W),Beyna(T),Auf der Horst(... Front Oncol 2026-00-00

...BRCA1/2, and ERBB2, enables the development of individualized therapeutic strategies. We report here a patient with KRAS...

Chao(Z),Li(L),Hao(X),Peng(H),Wang(Y),Zhang... J Clin Invest 2026-04-01

...BRCA1/2 mutations. While the survival benefits conferred by PARPi may extend beyond this specific patient population bas...

Singh(M),Betgeri(SN),Kakar(SS) J Ovarian Res 2026-01-28

...BRCA1/2 status, and histopathology offer only a partial view of disease biology, often leading to suboptimal and empiric...

Dimitrijevs(P),Makrecka-Kuka(M),Arsenyan(P... Biomolecules 2026-01-19

...BRCA1/2 mutations. Nevertheless, the rational design of mitochondria-targeted PARP inhibitors capable of selective mitoc...

Irving(E),Morcavallo(A),Vohhodina-Tretjako... Cancers (Basel) 2026-01-20

...BRCA1/2 mutations. However, resistance to PARPi remains a clinical challenge, with restoration of BRCA1 function via hyp...

Inić(Z),Žegarac(M),Krivokuća(A),Živković(O... Cancers (Basel) 2026-01-21

...BRCA1, BRCA2, CHEK2, PALB2). Disease recurrence occurred in 30%. Median follow-up was 53 months. Median disease-free sur...

Hu(Y),Wu(J),Sun(L),Xie(Z),Li(M),Yuan(L),Hu... Biomedicines 2026-01-14

...BRCA1/2 mutation rates. Extracellular vesicles (EVs) play a pivotal role in TNBC progression. This study aimed to analyz...

Kawczak(P),Bączek(T) J Clin Med 2026-01-14

...BRCA1/2 alterations. PSMA-directed RLT offers a survival advantage in PSMA-positive mCRPC following AR pathway inhibitio...

Robaczyńska(J),Kiljańczyk(M),Stachowski(A)... Hered Cancer Clin Pract 2026-01-29

...BRCA1-related ovarian cancer. In all primary and metastatic brain tumours, genetic testing for germline mutations of hig...

Chua(GNL),Beckwitt(EC),Miller-Browne(V),Yu... Cell 2026-02-19

...BRCA1 C-terminal homology (BRCT) domain of Rfc1, and mutation of its DNA-binding residues causes sensitivity to genotoxi...